title: Screening for prostate cancer. How can patients give informed consent?
abstract: Many urologists in North America are increasingly enthusiastic about prostatic cancer screening. Annual digital rectal examination is almost universally endorsed, and prostate-specific antigen testing is favored by most. But doctors really should not screen by either method without patients' informed consent. However, the information required for informed consent is complex and contradictory, difficult for physicians to give and for patients to absorb.
authors.affiliation: Family Medicine Centre, Queen Elizabeth Hospital, Montreal.
authors.forename: K G
authors.initials: KG
authors.lastname: Marshall
mesh_terms: D003144:Communication Barriers; D030881:Disclosure; D006801:Humans; D007258:Informed Consent; D038622:Internationality; D008297:Male; D008403:Mass Screening / Q000379:methods*; D010808:Physical Examination; D010817:Physician-Patient Relations; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000097:blood / Q000175:diagnosis / Q000517:prevention & control* / Q000523:psychology; D018570:Risk Assessment; D035501:Uncertainty; D014572:Urology
chemical_list: D017430:Prostate-Specific Antigen